Study to Evaluate the Effect of Nicotinamide Riboside on Immunity
Atherosclerosis, Diabetes, Coronary Artery Disease
About this trial
This is an interventional basic science trial for Atherosclerosis focused on measuring Inflammasome, Sirt3, Nicotinamide Riboside, Fasting
Eligibility Criteria
- INCLUSION CRITERIA:
As this is a pilot study, the age-range and BMI range of subjects will be restricted to potentially reduce metabolic variables associated with a wide age- and BMI-range.
- Males and females between the ages of 18 and 39
- BMI between 18.5 and 29.9
- Agrees to comply with study procedures and maintain current level of physical activity and dietary intake throughout the study.
- Female subjects of child-bearing ability willing to commit to reliable contraception while participating in the study.
EXCLUSION CRITERIA:
- Subjects with an acute or chronic illness as per history, on laboratory analysis or requiring medications to manage disease.
- Subjects taking vitamins or supplements or any medications, except oral contraceptives, within 4 weeks of participation into this study.
- BMI <18.5 or >29.9.
- Female subjects who are pregnant or lactating.
- Subjects who have donated blood or participated in another clinical trial involving blood draws in the last 8 weeks.
- Subjects who use nicotine products including chewing tobacco, vaporizer, gum, cigarette or patch form within three months.
- Any other medical condition that, in the opinion of the Principal Investigator, might put the subject at risk of harm during the study or might adversely affect the interpretation of the study data.
Sites / Locations
- National Institutes of Health Clinical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Arm 1
Arm 2
Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.